Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, has announced its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $37.3 million for the quarter, compared to a net income of $23.8 million in the same period in 2024. Total revenue for the quarter was $37.9 million, with U.S. XPOVIO® (selinexor) net product revenue reaching $29.7 million, marking a 6% increase compared to the second quarter of 2024. Karyopharm has reaffirmed its full-year 2025 total revenue guidance, projecting figures between $140 million and $155 million. The guidance for U.S. XPOVIO net product revenue has been updated to a range of $110 million to $120 million. The company also stated its intention to explore financing transactions and strategic alternatives to extend its cash runway and maximize value. As of June 30, 2025, Karyopharm's cash, cash equivalents, restricted cash, and investments totaled $52.0 million, down from $109.1 million as of December 31, 2024. Additionally, the company highlighted its ongoing clinical development programs, noting that new patient screening for the Phase 3 SENTRY trial in myelofibrosis is expected to close this week, with top-line results anticipated in March 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.